Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Reiteration

Reiteration

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration
  • Tech

Nutanix’s Internal Investigation Limits Outlook, Still Analysts Expect Minimal Impact, Remain Optimistic On Moderate Deal Elongation

By Anusuya Lahiri
March 7, 1:07 PM
Needham analyst Mike Cikos reiterates Nutanix Inc (NASDAQ: NTNX) 

NTNX

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

EF Hutton Reiterates Buy on Small Pharma, Maintains C$5 Price Target

By Benzinga Newsdesk
March 7, 12:27 PM
EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.

TSXV:DMT

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target

By Benzinga Newsdesk
March 7, 12:24 PM
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.

NVCT

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $11 Price Target

By Benzinga Newsdesk
March 7, 12:23 PM
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $11 price target.

OCUL

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Cantor Fitzgerald Reiterates Overweight on Allakos, Maintains $7 Price Target

By Benzinga Newsdesk
March 7, 9:49 AM
Cantor Fitzgerald analyst Jennifer Kim reiterates Allakos (NASDAQ:ALLK) with a Overweight and maintains $7 price target.

ALLK

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Benchmark Reiterates Buy on Quanex Building Prods, Maintains $31 Price Target

By Benzinga Newsdesk
March 7, 9:35 AM
Benchmark analyst Reuben Garner reiterates Quanex Building Prods (NYSE:NX) with a Buy and maintains $31 price target.

NX

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

RBC Capital Reiterates Sector Perform on MFA Finl, Maintains $11 Price Target

By Benzinga Newsdesk
March 7, 9:04 AM
RBC Capital analyst Kenneth Lee reiterates MFA Finl (NYSE:MFA) with a Sector Perform and maintains $11 price target.

MFA

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

RBC Capital Reiterates Outperform on Chimera Investment, Maintains $7 Price Target

By Benzinga Newsdesk
March 7, 9:01 AM
RBC Capital analyst Kenneth Lee reiterates Chimera Investment (NYSE:CIM) with a Outperform and maintains $7 price target.

CIM

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

RBC Capital Reiterates Outperform on American Water Works, Maintains $180 Price Target

By Benzinga Newsdesk
March 7, 8:57 AM
RBC Capital analyst Shelby Tucker reiterates American Water Works (NYSE:AWK) with a Outperform and maintains $180 price target.

AWK

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Credit Suisse Reiterates Outperform on Inhibrx, Maintains $46 Price Target

By Benzinga Newsdesk
March 7, 8:39 AM
Credit Suisse analyst Judah Frommer reiterates Inhibrx (NASDAQ:INBX) with a Outperform and maintains $46 price target.

INBX

Posts pagination

Previous 1 … 261 262 263 … 399 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service